Comparison of the effects of D-003, a mixture of high-molecular-weight aliphatic acids from sugarcane wax, and pravastatin on bones and osteoclast apoptosis of ovariectomized rats

Drugs under Experimental and Clinical Research

Volumn 31, Issue 5-6, 2005, Pages 181-191

  Mendoza, S ^a   Noa, M ^a   Mas R ^a   Mendoza, N ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC CARBOXYLIC ACID; BIOCHEMICAL MARKER; D 003; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PRAVASTATIN; PREDNISOLONE; STATINE DERIVATIVE; SUGARCANE WAX; UNCLASSIFIED DRUG; WAX;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE CELL; CELL DIFFERENTIATION; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG EFFECT; DRUG MIXTURE; ENZYME REGULATION; FEMALE; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; RAT; SUGARCANE;

ANIMALS; APOPTOSIS; BONE AND BONES; BONE RESORPTION; FATTY ACIDS; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSTEOCLASTS; OVARIECTOMY; PRAVASTATIN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SACCHARUM;

EID: 30144441521     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Watts N.B. Osteoporosis: Prevention, detection and treatment. J. Med. Assoc. Ga., 86(3), 224, 1997.
2. Looker A.C., Johnston G.G., Wahner H.W., et al. Prevalence of low femoral bone density in older US women from NHANES III. J. Bone Miner. Res., 10, 796, 1995.
3. Bagi C., Ammann R, Rizzoli R., Miller S. Effect of estrogen deficiency on cancellous and cortical bone structure and strength of the femoral neck in rats. Calcif. Tissue Int., 61, 336, 1997.
4. Thompson D., Simmons H., Pirie C., Ke H. FDA guidelines and animal models for osteoporosis. Bone, 17, 125, 1995.
5. Doggrell S.A. Present and future pharmacotherapy for osteoporosis Drugs Today, 39(8), 633, 2003.
6. Delmas P. Treatment of postmenopausal osteoporosis. Lancet, 359, 2018, 2002.
7. Russell R.G., Rogers M.J., Frith J.C., et al. The pharmacology of biphosphonates and new insights into their mechanism of action. J. Bone Min. Res., 14(Suppl. 2), 53, 1999.
8. Luckman S.P., Hughes D.E., Coxon RR, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res., 13, 581, 1998.
9. Fisher J.E., Halasy J.M., Masarachia P.J., et al. Alendronate mechanism of action: Inhibition of osteoclastogenesis and bone resorption are mimicked by lovastatin and blocked by geranylgeraniol. Bone, 23, S339, 1998.
10. van Beek E.R., Pieterman E., Cohen L., et al. Nitrogen-containing bisphosphonales inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem. Biophys. Res. Commun., 255, 491, 1999.
11. van Beek E.R., Löwik C., van der Pluijm G., Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J. Bone Miner. Res., 14, 722, 1999.
12. Fisher J.E., Rogers M.J., Halasy J.M., et al. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA, 96, 133, 1999.
13. Fisher J.E., Halasy J.M., Masarachia P.J., Wesolowski G., Rodan G.A., Reszka A.A. Alendronate mechanism of action: Inhibition of osteoclastogenesis and bone resorption are mimicked by lovastatin and blocked by geranylgeraniol. Bone, 23, 339, 1998.
14. Manolagas S. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. End. Rev., 21, 115, 2000.
15. Mundy G., Garret R., Harris S., et al. Stimulation of bone formation in vitro and in rodents by statins. Science, 286, 1946, 1999.
16. Garrett I.R., Gutiérrez G., Mundy G.R. Statins and bone formation. Curr. Pharm. Des., 7, 715, 2001.
17. Ohnaka K., Shimoda S., Nawata H., et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys. Res Commun., 287, 337, 2001.
18. Bauer D.C. HMG CoA reductase inhibitors and the skeleton: A comprehensive review. Osteopor. Int., 14, 273, 2003.
19. von Stechow D., Fish S., Yahalom D., et al. Does simvastatin stimulate bone formation in vivo? BMC Musculoskeletal Disorders, 4, 1471, 2003.
20. Maritz F.J., Conradie M.M., Hulley P.A., et al. Effect of statins on bone mineral density and bone. Histomorphometry in rodents. Arterioscler. Thromb. Vasc. Biol., 21, 1636, 2001.
21. Oxlund H., Andreassen T.T. Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone, 34, 609, 2004.
22. Mostaza J.M., De la Piedra C., Curiel M.D., et al. Pravastatin therapy increases procollagen I N-terminal propeptide (PINP), a marker of bone formation in post-menopausal women. Clin. Chim. Acta., 308, 133, 2001.
23. Reid I.R., Hague W., Emberson J., Baker J., et al. Effecf of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial. Long-term intervention with pravastatin in ischaemic disease. Lancet, 357, 509, 2001.
24. Sugiyama M., Kodama T., Konishi K., et al. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun., 271, 688, 2000.
25. Parhami F., Morrow A., Balucan J., Tintut Y. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol., 17, 680, 1997.
26. Xu H., Watkins B., Seifert M. Vitamin Estimulates trabecular bone formation and alters epiphyseal cartilage morphometry. Calc. Tissue Int., 57, 293, 1995.
27. Mas R. D-003: A new substance with promising lipid modifying and pleiotropic effects for atherosclerosis management. Drugs Future, 29, 773, 2004.
28. Menéndez R., Mas R., Amor A.M., et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol. Res., 44, 299, 2001.
29. Gárnez R., Mendoza S., Mas R., et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr. Then Res. Clin. Exp., 61, 8, 2000
30. Mendoza S., Garnez R., Mas R., et al. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits. Int. J. Tissue React., XXV, 81, 2003.
31. Gámez R., Mendoza S., Mas R., et al. Comparison of the cholesterol-lowering effects and toxicity of D-003 and lovastatin on normocholesterolemic rabbits. Drugs RD, 4, 219, 2003.
32. Menéndez R., Más R., Pérez J., et al. Oral administration of D-003, a mixture of very long chain saturated fatty acids, prevents casein-induced endogenous hypercholesterolemia in rabbits. Can. J. Physiol. Pharmacol., 82, 22, 2003.
33. Castaño G., Mas R., Fernández L., et al. Assessment of the effects of D-003, a new antiplatelet and lipid-lowering compound, in healthy volunteers. Drugs RD, 3, 337, 2002.
34. Castaño G., Menéndez R., Mas R., et al. Effects of D-003 on lipid profile and lipid peroxidation in healthy volunteers. Clin. Drug Invest., 23, 193, 2003.
35. Castaño G., Mas R., Fernández L., et al. Effects of D-003 (5-40 mg/day) on lipid profile of patients with type II hypercholesterolemia: A phase II clinical study. Clin. Drug Invest., 23, 789, 2003
36. Menéndez R., Mas R., Pérez Y., et al. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty acids. Can. J. Physiol. Pharmacol., 80, 13, 2002.
37. Noa M., Más R., Mendoza S., Gámez R., Mendoza N. Effects of D-003, a mixture of high molecular weight aliphatic acids from sugar cane wax, on bones from ovariectomized rats. Drugs Exp. Clin. Res., 30, 35, 2004.
38. Noa M., Mendoza S., Mas R., Mendoza N., Léon F. Effects of D-003, a mixture of very high molecular weight aliphatic acids from sugar cane wax, on prednisolone-induced osteoporosis in Sprague Dawley rats. Drugs RD, 5, 281, 2004.
39. Pytlik M., Janiec W., Misiarz-Myrta M., Gubala I. Effects of simvastatin on the development of osteopenia caused by ovariectomy in rats. Pol. J. Pharmacol., 55, 63, 2003.
40. Mosekilde L., Danielsen C., Knudsen B. The effect of aging and ovariectomy on the vertebral bone mass and biochemical properties of mature rats. Bone, 14, 1, 1993.
41. Parfitt A., Drezner M., Glorieux F, et al. Bone histomorphometry. Standardization of nomenclature, symbols, and units. J. Bone Min. Res., 2, 595, 1987
42. Coro P.M., Borrajero I. DIGIPAT. Un sistema cubano para morfometría de imágenes. Rev. Latinoam. Patol., 39, 9, 1996.
43. Sanders E.J. Method for detecting apoptotic cells in tissues. Histol. Histopathol., 12, 1169, 1997.
44. Weinstein R., Richard W., Nicholas R., et al. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J. Clin. Endocrinol. Metab., 85, 2907, 2000.
45. Gohel A., McCarthy M.B., Gronowicz G. Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinolology, 140, 5339, 1999.
46. Zhang F.L., Casey P.J. Protein prenylation: Molecular mechanisms and functional consequences. Annu. Rev. Biochem., 65, 241, 1996.
47. Staal A., Frith J.C., French M.E., et al. The ability olstatins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J. Bone Miner. Res., 18, 88, 2003.
48. Yaturu S. Skeletal effects of statins. Endocr. Pract., 9, 315, 2003.
49. Pritchett J.W. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin. Orthop., 386, 173, 2001.
50. Weinstein R., Manolagas S. Apoptosis and osteoporosis. Am. J. Med, 108, 153, 2000.
51. Plotkin L., Weinstein R., Parfitt A.M. Prevention of osteocyte and osteoblast apoptosis by biphosphonates and calcitonin. J. Clin. Invest., 104, 1363, 1999.
52. Weinstein R., Jilka R., Parfitt M., Manolagas S. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J. Clin. Invest., 102, 274, 1998.